First Decision, First Line of SDS Defense
The NK soybean portfolio offers industry-leading SDS-resistant varieties to help protect against Sudden Death Syndrome.
Seed selection is one of the first decisions a grower makes each season. If a soybean field has a history of Sudden Death Syndrome (SDS), this investment decision is even more crucial because the soybean variety is the first line of defense against the yield-limiting disease.
“It really all starts with that variety decision,” says Jason Bond, Ph.D., professor and plant pathologist at Southern Illinois University. “It’s amazing that something so early in the season has such an impact on the foliar symptoms that you’re looking at in August. But it all starts with that seed, that pathogen and the conditions at that time.”
The NK® soybean portfolio offers industry-leading SDS-resistant varieties to help protect against the disease. Across all relative maturities, Syngenta soybean varieties have consistently rated better than offerings from Pioneer® and Asgrow® when it comes to SDS genetic resistance scores.1
“NK has one of the longest-running soybean breeding programs on the continent, with more than 50 years of experience,” says Andy Heggenstaller, Ph.D., head of agronomy at Syngenta Seeds. “We maintain a clean conventional breeding effort that allows for continued selection focused only on high yield and defensive traits like SDS and no slowed progress from selection of herbicide trait performance. This elite collection of conventional breeding lines can then be used to quickly introgress new herbicide traits like we did recently with the Enlist E3® soybean herbicide trait.”
That’s how Syngenta delivers trait choice rapidly yet with confidence that its varieties will have high yield potential and defensive protection in growers’ fields.
1. According to independent SDS rating scores from Syngenta, Pioneer and Monsanto. Data from 2014 trials.
Learn more about the @NKSeeds #soybean portfolio, which offers industry-leading varieties to help protect against Sudden Death Syndrome.
click to tweet 
“It really all starts with that variety decision,” says Jason Bond, Ph.D., professor and plant pathologist at Southern Illinois University. “It’s amazing that something so early in the season has such an impact on the foliar symptoms that you’re looking at in August. But it all starts with that seed, that pathogen and the conditions at that time.”
The NK® soybean portfolio offers industry-leading SDS-resistant varieties to help protect against the disease. Across all relative maturities, Syngenta soybean varieties have consistently rated better than offerings from Pioneer® and Asgrow® when it comes to SDS genetic resistance scores.1
These better scores are thanks in part to the scientists who began work on SDS phenotyping in 1995 at a Syngenta legacy company in St. Joseph, Illinois, as well as today’s Syngenta scientists who continue innovating SDS solutions. SDS phenotyping is the process of measuring and analyzing the physical expression of genes in a plant’s DNA that are responsible for a particular trait.It really all starts with that variety decision. It’s amazing that something so early in the season has such an impact on the foliar symptoms that you’re looking at in August.
“NK has one of the longest-running soybean breeding programs on the continent, with more than 50 years of experience,” says Andy Heggenstaller, Ph.D., head of agronomy at Syngenta Seeds. “We maintain a clean conventional breeding effort that allows for continued selection focused only on high yield and defensive traits like SDS and no slowed progress from selection of herbicide trait performance. This elite collection of conventional breeding lines can then be used to quickly introgress new herbicide traits like we did recently with the Enlist E3® soybean herbicide trait.”
That’s how Syngenta delivers trait choice rapidly yet with confidence that its varieties will have high yield potential and defensive protection in growers’ fields.
1. According to independent SDS rating scores from Syngenta, Pioneer and Monsanto. Data from 2014 trials.
share this article
